Inhibitors targeting VEGF and VEGFR are commonly used in the clinic, but only a subset of patients could benefit from these inhibitors and the efficacy was limited by multiple relapse mechanisms. In this work, the authors aimed to investigate the role of innate immune response in anti-angiogenic...
Accumulating preclinical data indicate that targeting the SIRPα/CD47 axis alone or in combination with existing targeted therapies or immune checkpoint inhibitors enhances tumor rejection. Although several CD47-targeting agents are currently in phase I clinical trials and demonstrate activity in...
Expressed on activated T and natural killer cells, 4-1BB/CD137 is a costimulatory receptor that signals a series of events resulting in cytokine secretion and enhanced effector function. Targeting 4-1BB/CD137 with agonist antibodies has been associated with tumor reduction and antitumor immunity...
Presented by The University of Texas MD Anderson Cancer Center and Creative Educational Concepts, Inc. (CEC) in collaboration with the Society for Immunotherapy of Cancer. This program is ideally suited for North American-based junior faculty, fellows, and postdoctoral researchers (MDs, DOs,...
04-16-2020 08:00 - 04-18-2020 20:00 CT Houston TX
From the Society for Immunotherapy of Cancer (SITC) for clinical oncologists, registered nurses, pharmacists, emergency physicians and the entire cancer care team, the Advances in Cancer Immunotherapy™ (ACI) post-program webinar recording for the Charleston event is provided here. The purpose of...
Advances in Cancer Immunotherapy™ Post-Program Webinar 2 (Charleston).mp4
Insufficient co-stimulation accounts for a great deal of the suboptimal activation of cytotoxic CD8 T cells (CTLs) and presumably unsatisfactory clinical expectation of PD1/PD-L1 therapy. Tumor-derived soluble NKG2D ligands are associated with poor clinical response to PD1/PD-L1 blockade therapy...
Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance antibody-dependent cellular cytotoxicity activity. The authors...
LUNGevity's Patient Education Series offers several comprehensive booklets and brochures written and illustrated clearly to help patients understand their diagnosis and treatment options as well as the support services available through LUNGevity. These materials will help you learn about lung...
Oncolytic viral (OV) therapy has become a promising cancer immunotherapy because of its potential effectiveness, specificity and long-lasting immunity. In this article the authors describe and characterize a novel cancer immunotherapy combining Sindbis virus (SV) vectors and the agonistic...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us